Eli Lilly has agreed to supply 300,000 vials of its COVID-19 antibody treatment in the US, pending the treatment's emergency approval by the Food and Drug Administration .It said the therapy, bamlanivimab, would be used in "high-risk" patients with mild-to-moderate COVID-19.
Eli Lilly said Wednesday it expects to manufacture 1 million doses of the antibody treatment by the end of year, with 100,000 doses ready to ship worldwide soon after authorization.The US government will initially pay $375 million for 300,000 vials of the antibody treatment if the FDA grants it an emergency use authorization , Eli Lilly said."The initial agreement is for delivery over the two months following an EUA and also provides the option for the U.S.
Hope they get a thank you card, is this the wholesale price we paying 🧐.
good
FFS it doesn't work. Trust big pharma?
대한민국 최근 뉴스, 대한민국 헤드 라인
Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.
출처: BusinessInsider - 🏆 729. / 51 더 많은 것을 읽으십시오 »
출처: BusinessInsider - 🏆 729. / 51 더 많은 것을 읽으십시오 »